Key takeaways
- Galleri is a blood test that looks for changes in DNA, called methylation, that can signal cancer, and in early research it has been found to detect more than 50 types of cancer, including many with no national screening program [1].
- The company that developed it, GRAIL, says in its US patient FAQ that the test is recommended for adults at elevated risk of cancer, such as people aged 50 or older, and should be used in addition to the screening your healthcare provider recommends, not instead of it [2].
- The accuracy picture is lopsided: about 99.5% of people without cancer get a correct negative result, but in the 2021 validation study the test picked up only 16.8% of stage I cancers [3]. The test can also give a wrong result, so a negative isn't a guarantee [4].
- England's NHS-Galleri trial, which enrolled 142,250 people aged 50 to 77, did not meet its main goal of reducing stage III and IV cancers, although fewer stage IV cancers were seen in the group offered the test [5]. Queen Mary University of London's news release quotes a researcher saying that longer follow-up is needed to understand what that means for cancer outcomes [5].
- Expect to pay for it yourself: GRAIL's US list price converts to about €860, and that doesn't include follow-up tests [6][7]. As of the UK National Screening Committee's May 2026 statement, no country has put a test like this into an organized screening program [8].
- A "Cancer Signal Detected" result is not a diagnosis [2]. It starts a round of follow-up tests, and in the US PATHFINDER 2 study the median time to a final answer was 48 days [2][9].
You heard about the Galleri test. Here's what it actually is.
The EU's 2022 recommendation on cancer screening backs organized programs for three cancers: breast, cervical and colorectal [10]. For lung and prostate cancer it asks countries to explore or pilot screening, and for stomach cancer it asks them to consider screening in regions where the disease is common [10].
Plenty of cancers fall outside that list. The NHS-Galleri trial's own information page names lung, pancreas and stomach cancers as types without national screening programs [1]. The Galleri test, developed by a company called GRAIL, is a new cancer screening test: one blood test that looks for a signal shared by more than 50 types of cancer [2][11].
It sounds almost too good to be true. That's why it's worth reading past the marketing before you decide anything.
We've talked with a lot of people weighing whether to pay for an early-detection blood test their doctor never brought up. The honest answer is more interesting than either the hype or the skepticism. This guide walks through how the Galleri cancer test works, who it's for, what the research shows, what your result means, what it costs, and the questions worth asking before you spend a euro on it.
What is the Galleri test?
The Galleri test is a multi-cancer early detection test, often shortened to MCED [3][5]. One blood sample, one result that tells you whether your blood carries a signal that many different cancers share [11][12].
That "many cancers at once" design is the whole point. Standard screening tests each target one cancer: mammography for breast cancer, HPV testing for cervical cancer and a stool test called FIT for bowel cancer [10]. Galleri instead looks for a signal that shows up across more than 50 cancer types, including pancreas, liver and ovarian cancers [11]. If you want the bigger picture of how tests like this differ, our article about what multi-cancer early detection (MCED) means and how these tests compare goes through it.
Here's the part the test's own information pages repeat, and so will we: this is a screening test, not a diagnosis [2]. A signal doesn't mean you definitely have cancer [1]. It tells you whether you should go looking. The test is meant to be used in addition to the screening your healthcare provider recommends, not instead of it [2]. And if you're invited to cancer screening, keep going [1].

How the Galleri test works (in plain English)
The science behind the GRAIL test sounds intimidating. It isn't, once you strip out the jargon.
What cell-free DNA and methylation actually mean
Start with the DNA in your blood. Cell-free DNA, or cfDNA, is DNA that circulates in the blood, and tumors shed some of it into the bloodstream [3]. The Galleri test looks at the DNA in your blood to see whether any of it might have come from cancer cells [1].
The trick is telling DNA that came from cancer cells apart from the rest. That's where methylation comes in: changes in the DNA that can be a signal that cancer might be present [1]. The assay targets a panel of more than 100,000 informative methylation regions and combines cfDNA sequencing with machine learning to detect cancer signals [3].
One thing Galleri isn't: a gene-reading test. It does not read the DNA code itself [1]. If inherited cancer risk is what's worrying you, raise it with your doctor as a separate question.
From blood draw to result: the three steps
On your end, it's a single blood sample, and GRAIL says no fasting is required [12][2]. Behind the scenes, the lab does three things [3]:
- It sequences the cell-free DNA in your blood and reads its methylation patterns.
- It runs those patterns through a machine-learning model that flags whether a cancer signal is present.
- If a signal turns up, it predicts which part of the body the signal most likely came from. This is called the cancer signal origin, or CSO.
You'll typically get your result about two weeks after your sample reaches the lab [2].
What the Galleri test can and can't detect
This is where being honest pays off, so let's be specific in both directions.
The cancers Galleri screens for
GRAIL says the test looks for a signal shared by more than 50 types of cancer, and its list includes [11]:
- Pancreatic, liver, gallbladder and bile duct cancers
- Ovarian, uterine and other gynecologic cancers
- Stomach, esophageal and other gastrointestinal cancers
- Head and neck cancers
- Lymphoma, leukemia and plasma cell myeloma
- Kidney, bladder and other urinary tract cancers
Many cancer types on that list have no national screening program [1]. Others on it, like breast and colon and rectum cancer, are already covered by recommended EU screening [11][10]. Remember that it's looking for one shared signal, not running 50 separate tests [11].
When the test does find a cancer, how early is it? Among the 151 people in the US PATHFINDER 2 study with a new primary cancer found through the test, 80 (53.0%) had a stage I or II cancer at diagnosis [9]. That's about half. The cancers the test never flagged are a separate question, and the accuracy section takes it on.
What it won't catch
Now the other side. The Galleri test does not detect a signal for all cancers, and both false positive and false negative results can occur [11].
Early-stage cancers are the hardest for it to see, and the accuracy section below puts numbers on that [3]. The validation study's authors also note that some slow-growing (indolent) cancers, like early-stage prostate cancer, shed less and are therefore less detectable by this approach [3].
I want to underline this one: a "No Cancer Signal Detected" result is not a guarantee. Cancer Research UK says plainly that the test is not perfect and can give a wrong result [4].
Who the Galleri test is designed for
The test isn't meant for everyone, and the company is fairly clear about that.
Eligibility and exclusions
GRAIL's patient FAQ, which says its information is intended for audiences in the United States only, describes Galleri as recommended for adults with an elevated risk of cancer, such as those aged 50 or older [2]. Age matters because it is the single biggest risk factor for cancer, as Cancer Research UK puts it [13].
In England, the NHS-Galleri trial enrolled people aged 50 to 77 [5]. A GP clinic in Leicester, The Health Suite, says it offers the test to adults aged 50 and over, and to younger patients with an elevated personal or family risk [12]. What counts as elevated risk is a question for your doctor.
There are exclusions, too. GRAIL says the test is not recommended for people who are pregnant, under 22 or undergoing active cancer treatment [2]. The Leicester clinic lists similar exclusions: pregnancy, age 21 or under and an active cancer diagnosis [12].
Here's a quick gut check before you go further:
| Galleri may be worth discussing if you... | Galleri is probably not right if you... |
|---|---|
| Are an adult at elevated risk, for example aged 50 or older [2] | Are under 22, pregnant or having active cancer treatment [2] |
| Are up to date with your standard screening | Plan to use it instead of your standard screening |
| Want to decide together with a doctor, not on your own | Would treat a negative result as a guarantee |
| Know who would arrange and pay for follow-up tests if a signal turns up | Haven't thought about what a positive result would involve |
Galleri test accuracy: what the research shows
If you take one section seriously, make it this one. The accuracy of the Galleri test is good in one way and limited in another.
Specificity vs. sensitivity in plain terms
Three numbers matter most. Specificity is how good a test is at not crying wolf. Sensitivity is how good it is at catching real cancer. Positive predictive value, or PPV, answers the question you'd ask after a positive result: how likely is it that I really have cancer?
On specificity, Galleri does well. The published figures:
- 99.5% in the 2021 validation study [3]
- 99.64% in the US PATHFINDER 2 study [9]
- Around 99.5% to 99.6% across the three screening rounds of the NHS-Galleri trial [5]
In plain terms, a false alarm is uncommon: Queen Mary University of London's news release says fewer than 1 in 200 tests in the NHS-Galleri trial resulted in a false positive [5].
Specificity doesn't tell you what a positive result means for you. For that, look at PPV. In PATHFINDER 2 the PPV was 60.3%, so about 4 in 10 positive results were false alarms [9]. In the NHS-Galleri trial, over 50% of the people who tested positive were diagnosed with cancer [5].
If the test finds a signal, it also predicts where in the body it came from. In the validation study that prediction was accurate in 88.7% of true-positive results [3].
A caution on all of these numbers: they come from different studies with different designs, so don't line them up like a league table. That's why the NHS-Galleri trial matters. Professor Peter Sasieni of Queen Mary University of London describes it as the first randomized controlled trial anywhere to evaluate a multi-cancer early detection blood test at this scale [5].
The early-stage detection gap
Now the limitation. Sensitivity is far higher for advanced cancers than for early ones, and early cancers are the ones screening is meant to catch. In the validation study, the test picked up 16.8% of stage I cancers, 40.4% of stage II, 77.0% of stage III and 90.1% of stage IV [3].
Across all cancer types and stages, PATHFINDER 2 reported a 12-month episode sensitivity of 39.3%, meaning the test flagged that share of the cancers diagnosed in the year after testing [9]. Cancer Research UK puts the early PATHFINDER 2 results in plain terms: 4 out of 10 people diagnosed with cancer had a positive Galleri test result [4].
There's a bigger question, too: does finding these signals earlier help people live longer? The EU's 2022 screening recommendation names a reduction in disease-specific mortality, or in incidence of invasive cancers, as the main indicator of how well screening works [10]. The UK National Screening Committee's position statement says that, on current evidence, a fall in late-stage (stage III and IV) cancer is considered the most promising stand-in measure for cancer deaths [8]. That's not a reason to dismiss the test. It's a reason to hold your expectations at the right level.
What the NHS-Galleri trial found
England's NHS-Galleri trial has now reported. It recruited 142,250 people aged 50 to 77 and randomly assigned them either to have their blood tested with the Galleri test or to receive usual NHS care [5].
Here is what Queen Mary University of London's news release reports [5]:
- The trial did not meet its primary endpoint of reducing the combined number of stage III and IV cancers.
- When stage IV cancers were looked at on their own (a pre-specified secondary outcome), their incidence was lower in the group offered the test.
- Specificity was around 99.5% to 99.6% across the three screening rounds.
- Over 50% of those who tested positive were diagnosed with cancer.
In plain terms, the main question the trial was built to answer did not come back as a yes. Professor Sasieni puts it this way: "Although we did not see a reduction in our primary endpoint of stage III and IV cancers combined, we observed fewer stage IV cancers among people offered the test, alongside an increase in cancers diagnosed at earlier stages" [5]. He adds: "Longer follow-up will be crucial to understanding what these findings could mean for cancer outcomes and the potential future role of multi-cancer early detection tests" [5].
The release says the NHS and other health organizations will consider the evidence from the trial, and that the results were published in the New England Journal of Medicine and Nature Medicine [5].
What "Cancer Signal Detected" vs. "No Cancer Signal Detected" means
There are only two possible results, and it helps to know exactly what each one does and doesn't tell you.
Reading your two possible results
"No Cancer Signal Detected" is what nearly everyone gets. In PATHFINDER 2, a cancer signal was detected in 0.90% of participants, so about 99 in 100 people got this result [9]. It means the test didn't find a cancer signal in your blood. It does not mean cancer is impossible, because the test can give a wrong result [4]. And it's not a reason to skip your regular screening appointments [1].
"Cancer Signal Detected" means the test found a signal that needs checking, along with a prediction of where in the body it may have come from [2][3]. It is not a cancer diagnosis [2]. It's a flag.
What happens after a positive signal
A "Cancer Signal Detected" result is followed by diagnostic testing to find out whether cancer is really there [2]. In PATHFINDER 2, the median time to reach a final answer was 48 days [9]. Follow-up can also be invasive: 46.3% of the people whose positive result turned out to be a false positive still had invasive procedures during follow-up testing, a category the study defined as surgical or nonsurgical procedures such as endoscopy and biopsy [9].
GRAIL says the price of the test does not include that diagnostic testing [6]. Ask before you book who would arrange and pay for follow-up in your country.
It's also possible the work-up finds nothing, and the wait for answers can run to weeks [9]. Think about how you'd cope with that before you take the test, not after.
How much the Galleri test costs and where to get it
Let's talk money. "Should I just pay for it?" is a fair question.
We couldn't find a euro price published by the manufacturer. GRAIL's US list price converts to about €860 at the European Central Bank's reference rate of 13 November 2026 [6][7]. Treat that as a ballpark, not a quote, because what a clinic in your country charges may differ.
| What | What we know |
|---|---|
| Test price | About €860, converted from GRAIL's US list price [6][7] |
| Follow-up tests | Not included in the test price [6] |
| In the NHS | Not approved for routine use [4] |
| Where it is offered | A GP clinic in Leicester, England, announced in August 2026 that it was one of the first private providers in the UK to offer it [12] |
| NHS-Galleri trial | Closed to recruitment [4] |
Prices change and providers differ, so confirm the current number before you commit, and budget for the chance of follow-up testing.
Is the Galleri test part of national screening in Europe?
Short answer: no. The UK National Screening Committee's position statement, published in The BMJ in May 2026, says that although multicancer detection tests are available through private purchase in some places, no country has yet implemented them within an organized screening program [8].
The committee says it is awaiting robust evidence on whether a multi-cancer screening program delivers meaningful net benefit at reasonable cost [8].
The EU's 2022 cancer screening recommendation sets a high bar for new tests. It asks countries to implement them in routine healthcare only after they have been evaluated in randomized controlled trials and if they have conclusive scientific evidence of efficacy [10]. NHS-Galleri is a randomized controlled trial, and it did not meet its main goal [5].
For comparison, in the United States GRAIL states that the Galleri test has not been cleared or approved by the Food and Drug Administration [2].
That doesn't make the test a scam, and it doesn't make it useless. It means the evidence needed to offer it to everyone isn't in yet [8]. If a provider in your country offers it, ask what approval and quality checks apply to the test there.
Benefits and limitations: a balanced look
Here are both sides, plainly.
| Worth getting excited about | Worth staying cautious about |
|---|---|
| One blood sample looks for a signal shared by more than 50 cancer types [11] | Misses many early-stage cancers: 16.8% of stage I cancers were detected in the validation study [3] |
| Can flag cancers that have no national screening program [1] | Benefit for cancer outcomes is not yet shown: the NHS-Galleri trial did not meet its main goal [5] |
| Very few false alarms: specificity of around 99.5% to 99.6% in the NHS-Galleri trial [5] | Not approved for routine use in the NHS, and offered privately by some clinics [4][12] |
| Predicts where in the body a signal may have come from [3] | Follow-up after a positive result took a median of 48 days to resolve in PATHFINDER 2 [9] |
| 53.0% of the first new cancers found through the test in PATHFINDER 2 were stage I or II [9] | A negative result can be wrong, which risks false reassurance [4] |
Here's a quick rulebook:
| ✓ Do | ✗ Don't |
|---|---|
| Use it alongside the screening your doctor recommends | Skip your mammogram, bowel screening or cervical screening because of it |
| Discuss every result with your doctor | Treat "No Cancer Signal Detected" as a guarantee |
| Ask who arranges and pays for follow-up testing | Make any treatment decision on the screen alone |
| Ask whether you're in the intended-use group | Assume more testing always means better health |
How the Galleri test compares to standard cancer screening
Think of Galleri and your standard screening as doing different jobs, not competing for the same one.
Organized screening in the EU is built around tests that each target one cancer: mammography for women aged 50 to 69, HPV testing for women aged 30 to 65 and a stool-based FIT test for people aged 50 to 74 [10]. The Council says the evidence shows screening works for breast, colorectal and cervical cancer, and to a limited extent for lung and prostate cancer [10]. They're narrow and deep.
Galleri is the opposite shape: broad rather than deep. It casts a wide net across more than 50 cancer types, many with no national screening program [1]. Its sensitivity is lower for early-stage cancers [3]. And whether it improves cancer outcomes isn't clear yet, which is why a researcher quoted in the NHS-Galleri news release calls longer follow-up crucial [5].
The sensible move is to keep your recommended screening first and consider Galleri, if at all, as an addition, not a swap [2]. If you're not sure which screening you should be having, our guide on what cancer screenings you should get by age, sex, and risk walks through the usual recommendations.

Should you get the Galleri test? Questions to ask your doctor
We're not going to tell you yes or no. That decision belongs to you and a clinician who knows your history. What we can do is hand you the questions that turn a sales pitch into an informed choice. Bring these to your appointment:
- Am I actually in the intended-use group for this test?
- Am I up to date on the screening recommended for my age and risk?
- Given my personal and family history, would this change what we'd do?
- If it comes back "Cancer Signal Detected," what's the follow-up plan, and who arranges and pays for it?
- If it comes back negative, will I be tempted to skip screening I shouldn't skip?
- Is there a more proven step I should take with this money first?
- What approval and quality checks apply to this test in my country?
You're entitled to ask every one of these, and you should leave with answers you understand.
The bottom line
The Galleri test can flag some cancers that have no national screening program [1]. In the NHS-Galleri trial, stage IV cancers were less common among people offered it [5]. But the trial did not meet its main goal, and what the test means for cancer outcomes isn't clear yet [5]. In its validation study, the test detected only 16.8% of stage I and 40.4% of stage II cancers [3]. And GRAIL's US list price converts to roughly €860, with follow-up tests on top and, as of May 2026, no national screening program behind it [6][7][8]. It can also start a round of follow-up tests that ends with a cancer diagnosis or with no cancer found [2][9].
So do this, in order: stay current on the screening already recommended for you, write down your family history and personal risk factors, and book a conversation with your doctor using the questions above. For more to read, browse our resource library. And if you're a young person with lived cancer experience, our free, moderated community connects you with peers across Europe.
The test is a tool. Whether it's the right tool for you is a question worth answering slowly.
References
[1] NHS-Galleri Trial. (2026, May 30). About the blood test. Retrieved November 15, 2026, from https://www.nhs-galleri.org/about-the-trial/galleri-test
[2] GRAIL, Inc. (n.d.). Frequently asked questions (FAQs) for patients. Galleri. Retrieved November 15, 2026, from https://www.galleri.com/patient/faqs
[3] Klein, E. A., Richards, D., Cohn, A., Tummala, M., Lapham, R., Cosgrove, D., Chung, G., Clement, J., Gao, J., Hunkapiller, N., Jamshidi, A., Kurtzman, K. N., Seiden, M. V., Swanton, C., & Liu, M. C. (2021). Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Annals of Oncology, 32(9), 1167-1177. https://doi.org/10.1016/j.annonc.2021.05.806
[4] Cancer Research UK. (2025, May 29). Galleri blood test. Retrieved November 15, 2026, from https://www.cancerresearchuk.org/about-cancer/tests-and-scans/blood-tests/galleri-blood-test
[5] Queen Mary University of London. (2026, September 23). Major NHS trial provides new evidence on multi-cancer blood test [News release]. https://www.qmul.ac.uk/news/latest-news/2026/medicine-and-dentistry/fmd/major-nhs-trial-provides-new-evidence-on-multi-cancer-blood-test.html
[6] GRAIL, Inc. (n.d.). How much does the Galleri test for cancer screening cost? Galleri. Retrieved November 15, 2026, from https://www.galleri.com/patient/the-galleri-test/cost
[7] European Central Bank. (n.d.). Euro foreign exchange reference rates. Retrieved November 15, 2026, from https://www.ecb.europa.eu/stats/policy_and_exchange_rates/euro_reference_exchange_rates/html/index.en.html
[8] Batson, S., Taylor-Phillips, S., Mackie, A., Given-Wilson, R., Halligan, S., Hackshaw, A., Callender, T., Hyde, C., Payne, K., Visintin, C., Thompson, D., Evans, D. G., Richards, M., & Shinkins, B. (2026). UK National Screening Committee position statement on evidence required for multicancer detection tests. The BMJ, 393, Article e089868. https://doi.org/10.1136/bmj-2026-089868
[9] Nabavizadeh, N., McDonnell, C., Kurbegov, D., Matrana, M., Gadgeel, S., Kim, R. H., Stipec, G., Oeffinger, K. C., Demeure, M. J., Lillard, J. W., Jr., Kaltman, R., Tran, J., Roth, A., Tahhan, S., Poklepovic, A., Richards, D., Lopatin, M., Marquez, C., McCusker, M., & Giridhar, K. V. (2026). Performance and safety of a multi-cancer early detection test: The PATHFINDER 2 study. Nature Medicine. https://doi.org/10.1038/s41591-026-04618-w
[10] Council of the European Union. (2022). Council Recommendation of 9 December 2022 on strengthening prevention through early detection: A new EU approach on cancer screening replacing Council Recommendation 2003/878/EC (2022/C 473/01). Publications Office of the European Union. https://op.europa.eu/en/publication-detail/-/publication/58fa4c44-7a89-11ed-9887-01aa75ed71a1/language-en
[11] GRAIL, Inc. (n.d.). Blood test to detect cancer signal presence. Galleri. Retrieved November 15, 2026, from https://www.galleri.com/what-is-galleri/types-of-cancer-detected
[12] The Health Suite. (2026, August 18). The Health Suite among first in UK to offer blood test that screens for more than 50 cancers [Press release]. News-Medical.Net. https://www.news-medical.net/news/20260818/The-Health-Suite-among-first-in-UK-to-offer-blood-test-that-screens-for-more-than-50-cancers.aspx
[13] Cancer Research UK. (2018, June 20). Age: The biggest risk factor for cancer. Cancer Research UK News. https://news.cancerresearchuk.org/2018/06/20/age-the-biggest-cancer-risk-factor/
This article is for educational purposes only and is not medical advice. Always consult your doctor or another qualified healthcare professional for guidance specific to your situation.

This content was created during the YARN project, co-funded under the EU4Health Programme in 2025-2028 (Grant Agreement No. 101219053).




